The astroglial protein S100B and visually evoked event-related potentials before and after antidepressant treatment

Hetzel, Guenter; Moeller, Olaf; Evers, Stefan; Erfurth, Andreas; Ponath, Gerald; Arolt, Volker; Rothermundt, Matthias

doi:10.1007/s00213-004-1999-z

Cited by 81 publications

(43 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, S100B was not different between males and females with minor depression, rather it differed between healthy males and females. This finding is in line with previous studies showing no sex differences in major depression (Arolt et al, 2002;Hetzel et al, 2005), but contradicts another one showing increased S100B in females with major depression (Yang et al, 2008). The differences between our and the former study might be attributed to the differences in the studied samples with regard to disease severity and age.…”

Section: Discussionsupporting

confidence: 86%

“…Alterations of peripheral biomarkers of brain structure and function might shed light on the pathological changes in central mechanisms. Brain derived neurotrophic factor (BDNF), S100B and neuron specific enolase (NSE) are among the most studied biomarkers in affective disorders, in particular major depressive disorder (Schroeter et al, 2002;Hetzel et al, 2005;Andreazza et al, 2007;Schroeter and Steiner, 2009;Kalia and Silva, 2015).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

First Evidence For Glial Pathology In Late Life Minor Depression: s100b Is Increased In Males With Minor Depression

et al. 2016

View full text Add to dashboard Cite

Minor depression is diagnosed when a patient suffers from 2 to 4 depressive symptoms for at least 2 weeks. Though minor depression is a widespread phenomenon, its pathophysiology has hardly been studied. To get a first insight into the pathophysiological mechanisms underlying this disorder we assessed serum levels of biomarkers for plasticity, glial and neuronal function: brain-derived neurotrophic factor (BDNF), S100B and neuron specific enolase (NSE). 27 subjects with minor depressive episode and 82 healthy subjects over 60 years of age were selected from the database of the Leipzig population-based study of civilization diseases (LIFE). Serum levels of BDNF, S100B and NSE were compared between groups, and correlated with age, body-mass index (BMI), and degree of white matter hyperintensities (score on Fazekas scale). S100B was significantly increased in males with minor depression in comparison to healthy males, whereas other biomarkers did not differ between groups (p = 0.10-0.66). NSE correlated with Fazekas score in patients with minor depression (r s = 0.436, p = 0.048) and in the whole sample (r s = 0.252, p = 0.019). S100B correlated with BMI (r s = 0.246, p = 0.031) and with age in healthy subjects (r s = 0.345, p = 0.002). Increased S100B in males with minor depression, without alterations in BDNF and NSE, supports the glial hypothesis of depression. Correlation between white matter hyperintensities and NSE underscores the vascular hypothesis of late life depression.

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Introductionmentioning

confidence: 99%

First Evidence For Glial Pathology In Late Life Minor Depression: s100b Is Increased In Males With Minor Depression

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Interestingly, this old/new effect did not normalize shortly after clinical remission [19] . Recent studies indicate that moderately increased S100B levels in major depression might be a factor contributing to changes in ERP parameters in major depression [20,26] . Dietrich et al [20] demonstrated that remitted depressive patients with increased S100B serum levels showed normal ERPs N2 and P3 amplitudes in contrast to reduced N2 and P3 amplitudes in patients with normal S100B levels.…”

Section: Introductionmentioning

confidence: 99%

S100B Serum Levels and Word Memory Processing in Remitted Major Depression as Reflected by Brain Potentials

Zhang

Rothermundt²,

Peters³

et al. 2009

Neuropsychobiology

Self Cite

View full text Add to dashboard Cite

Objective: Memory processes, as reflected by ‘old/new’ effects of event-related potentials (ERPs), have been shown to be impaired in depressed patients. This variability might be partly explained by biological factors. S100B is a glial calcium-binding protein with neuroplastic properties; S100B serum levels have been shown to be increased in depressive patients. The pathophysiologic role of S100B in depression, however, is not yet sufficiently understood. Methods: In the present study, ERPs recorded in a visual continuous word recognition paradigm were therefore investigated in patients with remitted major depression in relation to S100B serum levels. Results: Patients with moderately increased S100B serum levels (n = 6) showed a normal old/new effect in contrast to a reduced old/new effect in patients with normal S100B levels (n = 6) compared to aged-matched controls. Conclusions: These findings provide evidence of an association between S100B levels and memory processes in patients with recurrent depression and further suggest a neuroprotective role of moderately increased S100B serum levels in the course of affective disorders.

show abstract

“…S100B may induce neurogenesis [43] that is required for behavioral effects of antidepressants [44] . Four treatment studies showed that S100B decreases after successful antidepressant treatment [20,21,45,46] . Patients with increased S100B levels had a better therapeutic response than those with normal S100B levels [46] .…”

Section: Discussionmentioning

confidence: 99%

Circulating Cerebral S100B Protein Is Associated with Depressive Symptoms following Myocardial Infarction

Tulner¹,

Smith

Jonge

et al. 2009

Neuropsychobiology

View full text Add to dashboard Cite

Background: Prevalence of depressive symptoms in the post-myocardial infarction (MI) period varies from 8 to 30%. Cerebral damage after MI, caused by transient ischemia, an inflammatory response or both, may contribute to development of post-MI depression. S100B is an established protein marker of cerebral damage. In a pilot study, the authors assessed whether S100B serum levels are: (1) increased during the week after MI, and (2) related to depressive symptoms during index hospital admission and the year following MI. Methods: This pilot study is a substudy of the Myocardial Infarction and Depression Intervention Trial (MIND-IT). In 48 patients, serum levels of S100B were available at 1, 2, 3, 4 and 8 days following MI. Subsequently, in 27 patients, depressive symptoms were measured at 0, 3, 6, 9 and 12 months following MI with the Beck Depression Inventory (BDI). In 21 of the initial 48 patients, BDI data were lacking due to refusals to fill out BDI forms or missing data. Results: Significant and transient increases in serum S100B were observed in 81.3% of the 48 patients: 37.5% reached S100B serum levels comparable to serum levels found in acute brain injury (>0.20 μg/l) and 43.8% reached mildly elevated S100B serum levels comparable to serum levels found in depressive disorder (0.10–0.20 μg/l). In 18.7%, no S100B was detected in serum. Using non-parametric Spearman rank correlation tests, a trend towards an association was found between serum S100B and depressive symptoms during the post-MI year (ρ values between 0.16 and 0.53) in 27 patients who completed both the S100B serum study and the BDI study. Conclusion: Transiently elevated levels of S100B are suggestive of minor acute cerebral damage in the first days following MI and associated with depressive symptoms in the year following MI. Cerebral damage could be an important mechanism in the pathogenesis in a subtype of post-MI depression.

show abstract

The astroglial protein S100B and visually evoked event-related potentials before and after antidepressant treatment

Abstract: The neuroregenerative activity of moderately increased S100B levels in major depression might be a factor contributing to a decrease of prolonged ERP parameters in major depression during antidepressant treatment.

Cited by 81 publications

References 32 publications

First Evidence For Glial Pathology In Late Life Minor Depression: s100b Is Increased In Males With Minor Depression

First Evidence For Glial Pathology In Late Life Minor Depression: s100b Is Increased In Males With Minor Depression

S100B Serum Levels and Word Memory Processing in Remitted Major Depression as Reflected by Brain Potentials

Circulating Cerebral S100B Protein Is Associated with Depressive Symptoms following Myocardial Infarction

Contact Info

Product

Resources

About